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Abstract The Patient-Reported Outcomes Safety Event
Reporting (PROSPER) Consortium was convened to
improve safety reporting by better incorporating the per-
spective of the patient. PROSPER comprises industry,
regulatory authority, academic, private sector and patient
representatives who are interested in the area of patient-
reported outcomes of adverse events (PRO-AEs). It has
developed guidance on PRO-AE data, including the ben-
efits of wider use and approaches for data capture and
analysis. Patient-reported outcomes (PROs) encompass the
full range of self-reporting, rather than only patient reports
collected by clinicians using validated instruments. In
recent years, PROs have become increasingly important
across the spectrum of healthcare and life sciences. Patient-
centred models of care are integrating shared decision
making and PROs at the point of care; comparative
effectiveness research seeks to include patients as partici-
patory stakeholders; and industry is expanding its
involvement with patients and patient groups as part of the
drug development process and safety monitoring. Addi-
tionally, recent pharmacovigilance legislation from regu-
latory authorities in the EU and the USA calls for the
inclusion of patient-reported information in benefit–risk
assessment of pharmaceutical products. For patients,
technological advancements have made it easier to be an
active participant in one’s healthcare. Simplified internet
search capabilities, electronic and personal health records,
digital mobile devices, and PRO-enabled patient online
communities are just a few examples of tools that allow
patients to gain increased knowledge about conditions,
symptoms, treatment options and side effects. Despite
these changes and increased attention on the perceived
value of PROs, their full potential has yet to be realised in
pharmacovigilance. Current safety reporting and risk
assessment processes remain heavily dependent on
healthcare professionals, though there are known limita-
tions such as under-reporting and discordant perspectives
between patient reports and clinician perceptions of
adverse outcomes. PROSPER seeks to support the wider
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use of PRO-AEs. The scope of this guidance document,
which was completed between July 2011 and March 2013,
considered a host of domains related to PRO-AEs,
including definitions and suitable taxonomies, the range of
datasets that could be used, data collection mechanisms,
and suitable analytical methodologies. PROSPER offers an
innovative framework to differentiate patient populations.
This framework considers populations that are prespecified
(such as those in clinical trials, prospective observational
studies and some registries) and non-prespecified popula-
tions (such as those in claims databases, PRO-enabled
online patient networks, and social websites in general).
While the main focus of this guidance is on post-approval
PRO-AEs from both prespecified and non-prespecified
population groups, PROSPER has also considered pre-
approval, prespecified populations. The ultimate aim of this
guidance is to ensure that the patient ‘voice’ and perspec-
tive feed appropriately into collection of safety data. The
guidance also covers a minimum core dataset for use by
industry or regulators to structure PRO-AEs (accessible in
the online appendix) and how data, once collected, might
be evaluated to better inform on the safe and effective use
of medicinal products. Structured collection of such patient
data can be considered both a means to an end (improving
patient safety) as well as an end in itself (expressing the
patient viewpoint). The members of the PROSPER Con-
sortium therefore direct this PRO-AE guidance to multiple
stakeholders in drug safety, including industry, regulators,
prescribers and patients. The use of this document across
the entirety of the drug development life cycle will help to
better define the benefit–risk profile of new and existing
medicines. Because of the clinical relevance of ‘real-
world’ data, PROs have the potential to contribute impor-
tant new knowledge about the benefits and risks of
medicinal products, communicated through the voice of the
patient.
1 Introduction
Current methods for safety reporting and risk assessment
still rely heavily on healthcare professionals (HCPs). A
way to improve the quantity and/or quality of safety
information is to encourage patient-reported outcomes of
adverse events (PRO-AEs), which are more patient focused
and may have less formal data collection processes that do
not rely on input from HCPs. Some HCPs such as phar-
macists, however, might facilitate PRO-AE collection [1,
2]. HCPs will also retain a critical role in assessing the
causality between adverse events (AEs) and drugs, espe-
cially for individual cases of severe and fatal AEs.
Because of the varied nature of patient populations (see
Fig. 1), a range of different data collection tools, analytical
approaches and methodologies may need to be deployed to
meet different PRO-AE requirements. A classification
based on whether or not the relevant patient population is
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Fig. 1 Classification of PRO-AEs. PRO-AE patient-reported out-
come of adverse event. a Prespecified populations will have different
analytics to non-prespecified populations, with the latter being lower
in the quantitative hierarchy. Analytics used lower in this hierarchy
can also be utilised for populations higher up
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prespecified (rather than just pre- or post-approval) pro-
vides a rational basis for further subdividing the safety
populations [3].
For instance, the dataset is more structured and the
patient population is better defined in post-approval, pre-
specified populations (e.g. phase 4 clinical trials and pro-
spective observational studies) than in post-approval, non-
prespecified patient populations. However, even within the
non-prespecified group there are variations—for example,
some patient support websites use structured data templates
to collect PRO-AEs, whereas most websites have only
unstructured free text.
There are also distinctions between clinical trials, where
the denominator is clear and there are specific goals around
balancing safety and efficacy [4, 5], and safety surveillance
systems that may have no clear denominator representing
the total number of patients. There are also issues around
either defining a cohort or opening up reporting to any
patient, either voluntary or solicited.
Patient-reported outcome (PRO) data can be captured in
a structured way using a suitable instrument, which is a
specific reporting tool that through completion generates a
structured dataset. This could be a questionnaire or diary
along with supporting information such as training mate-
rials, scoring, etc.
The amount and nature of missing data, under-reporting
and bias are substantially affected by the specific data col-
lection approach taken. In the regulatory context, the
approach to collecting PROs for AEs may differ depending
on whether the aim is a comparative tolerability claim (i.e. a
product having a more favourable tolerability profile com-
pared with another) or just general documentation of AEs.
Tools used to capture PROs have become established in
areas such as assessing the quality of care delivered to
patients by providers and health-related quality of life
(HRQoL) measures used in clinical trials. In these fields,
PROs are based on methodologies that have been well
validated. In the UK National Health Service (NHS),
patient-reported outcome measures (PROMs) have been
used to measure patient outcomes for some planned sur-
gical interventions, such as hip and knee replacements,
varicose veins and hernia [6], but the ability to collect
PRO-AEs within this framework is currently relatively
limited.
The use of PRO instruments for capturing AE data is not
so well developed. Most progress has been made with the
collection of pre-approval PRO-AEs in clinical trials,
although there is also significant previous literature on
voluntary reporting [3]. Some PRO questionnaires given to
patients in trials cover potential adverse effects, and for
certain conditions such as HIV, there has been systematic
collection of symptoms from patients using checklists. The
National Cancer Institute (NCI) in the USA is also
developing a methodology for collecting PRO-AEs in
oncology trials based on a patient-reported outcomes ver-
sion of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE). In the epidemiological context, AE
outcome measures can be continuous variables or have
binary outcomes.
This guidance will consider if methodologies used to
collect pre-approval PRO-AEs could be modified for post-
launch studies with prespecified populations. The suc-
cessful use of PRO tools has suggested to some that
monitoring of AEs reported by patients (as well as their
care-givers and relatives, where appropriate) outside of the
framework of clinical trials should be routinely considered
in everyday practice, because it more closely represents the
patients’ self-evaluation of HRQoL [7]. However, some
signs or symptoms may be due to the disease rather than
the drug, and it is important to distinguish these.
The use of PRO-AE instruments outside of clinical trials
is also less well implemented. Whilst some countries have
previously developed web-based systems to enable con-
sumers to report post-approval suspected adverse reactions
(ARs) directly to the regulatory authority [e.g. Food and
Drug Administration (FDA) MedWatch, Medicines and
Healthcare Products Regulatory Agency (MHRA) Yellow
Card scheme, Australia TGA Blue Card scheme, Health
Canada Med Effect] in an attempt to address under-
reporting by HCPs, this approach has had only limited
success in capturing safety data [8, 9]. Recent EU legis-
lation means that there will be increased consumer
reporting of this type across member states.
Similarly, there are currently only a few non-regulatory
approaches aiming to capture PRO-AE data, including
PRO-AE-enabled patient support websites [10]. Whilst
popular with patients, these sites are primarily intended for
the purposes of patient support and education rather than as
PRO-AE instruments. The potential to mine AE data from
unstructured text derived from online health forums is
feasible, but needs further development before wider util-
isation [11].
Patient support programmes (PSPs), which are devel-
oped by companies to assist patients and/or HCPs in better
managing diseases and treatments, are already subject to
AE reporting requirements. PSPs, however, are typically
not specifically designed to collect PRO-AE data post
launch and may represent missed opportunities to collect
improved post-marketing safety data.
There is evidence [7] to suggest that collecting symptom
data directly from patients can be beneficial, leading to an
improvement in the accuracy and efficiency of symptom-
atic AE data gathering [12–14]. It is also clear that this is a
growth area, particularly in the unregulated social network
environment, and monitoring of this data is a concern for
health authorities.
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However, for industry, patients, academics and regula-
tors to make best use of this information, guidelines are
needed. The definitions, standards, methodologies and
utility of PRO-AEs set out in this guidance will support and
promote the use of PRO-AE instruments across the drug
life cycle. This PRO-AE guidance may also be applied to
other related situations, for example, the monitoring of
medical devices used by patients or potentially the data
generated by patient-worn devices (e.g. for the reporting of
falls).
2 Definition of a PRO-AE
It is important to clearly define what is meant by PRO-AEs
and to determine whether these are different from other
forms of consumer reports. There are established defini-
tions used by the European Medicines Agency (EMA) and
the US FDA for PROs in general and for AEs [15–17]. A
recommended definition for PRO-AEs based on these
resources, and used in this document, is as follows:
A PRO-AE is any untoward medical occurrence, whe-
ther or not considered treatment/intervention related, that is
reported or transmitted directly by the patient without
interpretation by a clinician or anyone else. PRO-AEs may
be collected by both structured and unstructured reports.
This definition includes information from patients
directly reporting their own experiences (e.g. symptoms)
and from patients transmitting data that they have received
(e.g. laboratory test results). Patient-reported symptoms
may be related to the drug or due to other factors, such as
the underlying disease, that represent AEs rather than
adverse drug reactions (ADRs). Although it can be argued
that patients may not always be able to distinguish between
symptoms, signs, safety events and ADRs, this should not
matter unduly, provided that AEs and ADRs are distin-
guished and appropriately interpreted.
There is some debate about whether PROs should be
covered by a narrower definition related only to the use of
validated instruments, which includes just a subset of all
patient self-reported data. For the purposes of this guid-
ance, PROs encompass the full range of self-reporting, as
the guidance proposes that an acceptable overarching
framework can be created, and that approaches that are
currently less validated may actually collect more clini-
cally applicable information as newer analytic methods
evolve.
Hence, PRO-AEs (whether structured or unstructured,
and prespecified or non-prespecified) include signs and
symptoms that are less severe and reflect tolerability,
more severe ARs that reflect safety issues, as well as
signs and symptoms that may be a precursor of more
severe ARs (e.g. febrile angina preceding the onset of
aplasia and systemic infection). In addition, abnormal
laboratory values that could be a precursor for a poten-
tially severe AR (e.g. neutropenia or liver injury) may be
considered as patient-transmitted outcomes. Abnormal
biological values may provide useful supporting infor-
mation, although there could be heterogeneous reporting
by patients.
There may be a limitation in adequately reporting some
symptoms for which patients may not be aware, e.g. cog-
nitive dysfunction or loss of memory, although in some
cases a patient’s relative, carer or HCP may identify these
to the patient, who subsequently reports them.
3 Scope
This guidance covers PRO-AEs from both the pre- and
post-approval environments, as shown earlier in Fig. 1. It
proposes definitions, methodologies, data collection tools,
datasets and analytic approaches for PRO-AE reporting
that are rigorous, transferable and consistent.
However, because the methods, tools and analytics for
pre-approval PRO-AEs are already relatively well docu-
mented [18, 19], the main focus of this guidance will be on
post-approval PRO-AEs from both prespecified and non-
prespecified populations. As the adoption of PRO-AEs in
clinical trials is well advanced, the transferability of
knowledge gained in this area will also be examined.
The main purpose for collecting post-approval AE data
is to enable companies and regulators to assess the ongoing
safety profile of a product, under real-use conditions, using
signal detection techniques. However, under-reporting,
incomplete data, and reporting bias currently limit the
utility of signal detection, and alternative methods of data
collection such as PRO-AEs need to be explored.
The goal of analysing PRO-AE data is to add to the
knowledge already provided by HCPs, when available,
increasing the likelihood and speed of detection of signals.
PRO-AEs can also be used complementary to traditional
data on efficacy and safety for benefit–risk analysis, risk
minimisation evaluation, and communication of safety
issues to patients. The collection of symptom-based PROs
is also important in many large post-approval studies to
better define (in terms of frequency, description and evo-
lution) symptoms that were previously reported in ran-
domised clinical trials.
Analysis of non-prespecified populations gives access to
much larger populations than can be achieved even from
observational studies, as well as reports and perspectives
on symptoms that are important to patients, but which are
often not reported to HCPs or remain unreported by
patients because of the sensitive nature of those symptoms.
Thus, the collection and analysis of PRO-AEs may increase
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the ability of finding new safety concerns (especially rare
safety issues that require large numbers of exposures to
detect) and also broadens the types of data collected
(events of concern specifically to the patient).
Although open questions may be used to elicit safety
information in the latter population, there may be a sig-
nificant risk of selection and reporting bias. Qualitative
analysis can be difficult and might potentially lead to false
signals if the population is heterogeneous and all relevant
factors are not identified and analysed. Therefore, careful
consideration must be given to both the questionnaire
design and any subsequent analytics to reflect this (Sects. 5,
6). The same considerations apply to data collected from
online patient communities.
4 Rationale for Wider Use of PRO-AEs
4.1 Problems with Current AE Data
Current safety reporting and risk assessment processes for
both prespecified and non-prespecified populations are
heavily dependent on input from HCPs and introduce a
number of limitations, as shown in Table 1, although they
still represent the current gold standard.
Despite these shortcomings, there may still be a reluc-
tance to adopt an approach that also includes PRO-AEs
because of:
• Regulatory constraints;
• Concerns about feasibility;
• Scepticism regarding the validity and reliability of
using patient-reported AE data;
• Higher data volumes needing review that might obscure
or reduce focus on key safety concerns;
• Added administrative requirements and cost;
• Limitations of the available questionnaires/methods;
• Industry concerns about the potentially high volume of
relatively ‘minor’ AEs reported by patients, and the
cost and practicality associated with processing them;
• Privacy issues, including control of patient information
collected and stored electronically.
However, these objections are not insurmountable, as
shown in Table 2, and have been successfully dealt with in
some clinical PRO safety systems, such as the NCI
approach.
Table 1 Problems with current AE data in prespecified and non-prespecified populations
Subject Prespecified populations Non-prespecified populations
Sensitivity/representative
data
Some current methods for detecting AEs in
clinical trials lack sensitivity [20]
A narrow and relatively small patient
population is enrolled into clinical trials.
Entries are usually made by the HCP and
hence tend to be biased towards that
perspective [21]
Medical records in non-trial populations are often incomplete,
possibly due to the patient not informing their HCP of any AEs.
Entries are also usually made by the HCP and may differ from
the patient perspective [7]
Early symptom detection Symptoms might be identified earlier in the
drug development life cycle if PRO-AEs
were more commonly used in clinical trials
Labelled ARs tend to be under-reported by HCPs in non-trial
situations since they are considered to be expected and therefore
of lesser importance [22, 23]
HCP are less likely to report non-serious events
Clinician detection of AEs Clinicians can underestimate the importance of patients’ symptoms [24, 25]
HCPs may concentrate on symptoms caused by drugs and not focus on capturing the significance of the symptoms
to the patient’s holistic experience while using the drug product [7]
HCP are more likely to report ARs that are known to be caused by drug effects (e.g. Stevens–Johnson Syndrome)
HCP are less likely to report events that have a high background rate
HCP versus patient
perspective
Clinicians may miss patient symptom-related AEs that patient self-reporting frequently captures [24, 25], which
can result in preventable AEs
Clinicians often miss baseline (pre-treatment) symptoms that patients may be experiencing—therefore these
symptoms may subsequently incorrectly be attributed to drug
Suboptimal patient-prescriber communication can lead to limited reporting of important safety issues [18]
Discordance between patient and prescriber perspectives may exist, so the patient’s perspective might be devalued
or overlooked completely [7]
Compatibility of verbatim
reporting terms
Data incompatibilities when symptoms
reported by patients are not controlled and
mapped to accepted medical terms
Data incompatibilities also arising between PRO-AE data and
HCP-recorded data captured in a regulatory system (e.g. MHRA
Yellow Card scheme) or by a manufacturer [26]
AE adverse event, AR adverse reaction, HCP healthcare professional, MHRA Medicines and Healthcare Products Regulatory Agency, PRO-AE
patient-reported outcome of adverse event
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4.2 When Could PRO-AE Data Be Collected?
PRO-AE data could potentially be collected at all stages of drug
development as well as post launch (see Fig. 2). Currently, the
majority of PRO-AEs are collected in phases 2 and 3, often
supporting more traditionally collected safety information.
A useful framework for subclassifying PROs would be
to consider their impact on measuring benefit–risk balance
at each stage along the drug development life cycle. For
instance, it has been reported that PRO-AE data from pre-
approval clinical trials have:
• Better described the patient’s underlying health and
functional status;
• Led to the detection of potentially serious AE symp-
toms earlier than clinician reporting [19].
Similar advantages to collecting PRO-AEs from post-
approval populations might be anticipated. A distinction
Table 2 Potential solutions to objections against use of PRO-AE instruments
Objection Current situation and/or potential solution
Perceived regulatory constraints Pre-approval—no regulatory requirement to prevent patients reporting
potential AEs in clinical trials, e.g. the FDA mandates only that sponsors
provide safety data during drug development and approval. In the EU
Good Clinical Practice and the Clinical Trials Directive, the requirement
is for the investigator to report AEs to the sponsor [18, 19]
Post-approval—currently, AEs in many regions have to be medically
approved (not necessarily by the treating HCP) before they can be
submitted as a serious case. There is increasing emphasis on patient
reporting of AEs by regulatory authorities. Although EU member states
now accept non-medically confirmed consumer reports, their collection
and content may be less robust
Concerns about feasibility and reproducibility in design Pre-approval—in numerous trials, instruments for outcome reporting by
patients have been shown to be a valid and reliable way [18, 19] of
collecting data on:
• Symptoms
• Health-related quality of life
• Compliance with a drug regimen
• Patient satisfaction with care
Post-approval—instruments for outcome reporting by patients have been
used successfully to collect the types of data listed above
Higher data volumes needing review that might obscure or reduce
focus on key safety concerns; added administrative requirements
and cost
Pre-approval—most of the necessary infrastructure is already in place,
since AE reporting is standard in clinical trials
Incremental costs can be minimised by using widely available, inexpensive
reporting technologies that rely on the internet or patients’ telephones
A resource-efficient review process can be conducted, with prioritisation of
the more serious safety issues. Regulators can encourage a proportionate
risk approach
Post-approval—as for pre-approval. Regularly screening by a Marketing
Authorisation Holder of internet and digital media under its management
or responsibility for potential reports of suspected adverse reactions is
required in EMA guidance [27]. Other specific monitoring might be
accommodated as organisations already have resources to review relevant
websites—all that would be required is additional prioritisation focused
on, for example, the main patient support groups
Limitations of the available questionnaires/methods Pre-approval—there are multiple measures that could be immediately
adopted or modified for this purpose, including the NCI PRO-CTCAE
initiative [28]
Post-approval—the field of instrument development has advanced
substantially in recent years, with standards that are now encoded in the
FDA guidance on PRO development. The use of smartphone applications
(‘apps’) for reporting is already underway in developing countries [29]
and allows greater freedom in data capture
AE adverse event, EMA European Medicines Agency, FDA Food and Drug Administration, HCP healthcare professional, NCI National Cancer
Institute, PRO patient-reported outcome, PRO-CTCAE patient-reported outcomes version of the Common Terminology Criteria for Adverse
Events
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can be drawn between PRO-AEs in specified populations
(either pre- or post-launch, with both utilising similar
methodologies) and those in patient populations not pre-
specified, which demand different methodologies.
Some of the PRO-AE measures that are well docu-
mented in the pre-approval space could also be adapted for
non-prespecified, post-approval studies. However, issues
with the reporting time frame, completeness of data, lack of
medical confirmation, and the ability to accurately define
the numerator and denominator at risk (i.e. number of
subjects experiencing events as a proportion of total
number of subjects) mean that different or additional
approaches may be more appropriate for the post-approval,
non-prespecified group.
Post-approval PRO measurements could therefore be
used in:
• Screening to detect signals in the general population
and in observational cohorts;
• Controlled trials for more targeted assessments;
• Other PRO-AE-based approaches in post-authorisation
studies, for instance, the proactive follow-up of patients
after occurrence of an AE of special interest (which
may include a medical confirmation of the detected
events through the event-treating physician).
4.3 Benefits and Challenges of PRO-AE Data
Integrating the patient perspective into drug safety
reporting not only improves the accuracy of the data
collected but may also enhance the patient-centeredness
of clinical research. In fields such as oncology, where
symptoms are common and can substantially impair
patients’ functioning and quality of life, information
about patients’ experiences of AEs is essential for mul-
tiple stakeholders, including patients, drug developers,
regulators, and payers. The benefits of PRO-AEs are
summarised in Table 3.
Further advantages of PROs more generally, from a
benefit–risk perspective, are shown in Table 4.
There are also potential public health downsides to
patient adverse outcomes being disseminated without being
put into an appropriate benefit–risk context, e.g. causing
unnecessary alarm or leading to discontinuation of effec-
tive therapies. Safe and effective public communication of
benefit–risk should form part of any organised collection of











PRO-AEs may be collected in prespecified clinical 
trial populations, usually in phases 2 and 3
A wide range of PRO-AE
approaches may be considered
Fig. 2 PRO-AEs are applicable
at all stages of the medicinal
product life cycle. PRO-AE
patient-reported outcome of
adverse event
Table 3 Benefits of PRO-AEs to different stakeholders
Stakeholder PRO-AE benefits
Patients Patients facing a treatment decision wish to know
what they can expect in terms of symptoms,
based on the prior experiences of a ‘‘patient like
me.’’ However, there is a need to avoid patients
having access to PRO-AE data from other
patients in the pre-approval stage, as this could
further exacerbate the placebo effect/bias
results from clinical trials
In reality, a patient may not have significant input
into their treatment decision at the point of
prescription. They may seek more information
when they get home to know what to expect of
their medicine as well as medication
preferences
Drug developers Developers want to understand how well patients
will tolerate a product. This is particularly
relevant with oral therapies for which
compliance is strongly associated with
symptomatic side effects. PRO-AEs can be
useful in early-phase research towards
identifying tolerated dose levels and in pivotal
trials to compare tolerability between products
from the patient perspective
Regulators Regulators have long recognised the limitations
of symptomatic adverse event information
reported by clinicians in trials. A systematic,
patient-reported approach would increase
confidence in the fidelity of this information
toward balancing risks and benefits, so long as
the report was detailed and complete
Payers Payers want to better understand the side effects
of specific treatments, because it helps to
predict the utilisation of healthcare services and




PRO-AEs can provide the clinician with
information of value on a subjective experience,
which when combined with the physician
perspective based on experience and training
provides a more accurate understanding of the
patient’s symptoms. The latter is improving the
measurement of symptoms in clinical trials and
practice
PRO-AE patient-reported outcome of adverse event
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PRO-AEs, in both prespecified and non-prespecified
populations.
However, how such communication takes place for
unplanned, unstructured, spontaneously posted, web-based
PRO-AEs is more challenging. It can be reasonably argued
that meaningful analysis of such information offers the
opportunity for objective communication of the actual
risks, perhaps through regulators or other trusted third
parties, thus representing a significant improvement on the
current situation.
Other perceived disadvantages of PRO-AEs include costs,
the possibility of swamping safety signal with noise, exacer-
bation of the placebo effect at pre-approval phases, and the
possibility that the PRO-AE data is not independent of the
AEs collected by physicians in pre- and post-approval phases,
although most of these issues can be resolved with appropriate
methodology. In fact, the two data sources might be highly
correlated and therefore of low added value, although still of
confirmatory benefit. However, it is rarely possible to match
up patient information on reports in the safety database,
usually because limited identifying information is provided
for patients from non-standardised data collection schemes.
There is a significant risk of having duplicates in the database
for cases received from multiple sources.
This guidance does not attempt to discuss the merits of
the newer forms of web-based communication of such
information compared with the traditional processes, as this
issue has a much wider scope than PRO-AEs and tran-
scends the whole topic of better public communication of
benefit–risk balance.
4.4 Evidence Supporting the Use of PRO-AE Data
There is now considerable evidence from clinical trials that
patient and clinician reports of AEs, particularly those
based on subjective symptoms during cancer treatment, can
provide diverse yet complementary data. For example, it
has been shown that including information gathered
directly from study participants via PRO measures
improved the predictive accuracy of clinician-reported
CTCAEs [19, 30]. Although clinicians were able to predict
survival well, patient reporting of symptomatic toxicities
better reflected the patient’s underlying health state and
functional status.
Patient reporting also appears to detect potentially
serious AEs or their symptoms earlier than clinician
reporting. This is well demonstrated by the timing and
cumulative incidence of patient versus clinician reporting
of severe diarrhoea in the irinotecan/fluorouracil/leucov-
orin arm of the NCI intergroup trial N9741 [31], in which
many life-threatening gastrointestinal serious AEs were
detected [32], as well as subjectively reported AEs in
musculoskeletal and central nervous systems.
Evidence suggests that patients are best placed to report
their subjective experiences, whereas HCPs contextualise
that experience in terms of the disease [19]. Both views are
valid and contribute towards improving the understanding
of the treatment of AEs if recognised as such by regulators.
Industry is thus incentivised to develop mechanisms that
allow both datasets to be fully utilised [19].
For drugs already on the market, there is some evidence
of increasing consumer activity in the reporting of AEs to
regulators. However, the fastest rate of growth in potential
consumer-reported AEs appears to be through non-regu-
latory, PRO-enabled patient websites [3].
5 Developing PRO Instruments for AEs
The FDA has produced guidance [16] and the EMA [17]
has published a reflection paper on PRO measures in
Table 4 Further potential benefits of PROs in general
Benefits
Pre-approval
• PRO end points in late-phase clinical trials support treatment
benefit claims that describe a patient’s symptoms or ability to
function
• Treatment modifications, symptom control and side-effect
prevention techniques (risk minimisation) can be evaluated in
late-phase clinical trials using PRO data
• Healthcare researchers and policymakers can use PRO data from
late-phase trials to study the burden of disease on the targeted
patient population
• While manufacturers and researchers use late-phase clinical
trials to corroborate the safety and long-term effectiveness of
their drug, incorporating PRO end points could ensure focus on
patient-centred healthcare delivery
• Better dose finding taking into consideration the patient
perspective
Post-approval
• Ability to be truly ‘patient-centric’—such data can then be used
to guide improvements, providing a competitive advantage for a
sponsor
• Potential ability to assess/evaluate how well risk minimisation
activities are working
• The combination of drugs with the best benefit–risk profile can
often vary among patient populations, so it becomes necessary to
conduct the assessment from the patient’s perspective, using
PRO measures, which can result in improved compliance
• Resource allocation, drug costs, and premium reductions can be
made through the extraction of information from post-marketing
surveillance data
• Valuable real-world safety data may be obtained from alternative
sources, through which patients may be more willing to provide
data than using standard channels
• Patient-reported AEs predict emergency room visits and
utilisation of services
AE adverse event, PRO patient-reported outcome
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support of label claims. The FDA guidance states that PRO
instruments can be used to measure important safety con-
cerns if those concerns represent symptoms or signs that
are best captured from the patient perspective.
A challenge remains of how to integrate PRO-AEs into a
benefit–risk assessment, e.g. post-approval. Usually, PRO-
AEs will be collected without PRO-FEs (favourable
events). If there is lack of perceived efficacy, should
patients report this as an AE? It is possible that a few years
after marketing, the AE profile of the drug may be defined
more accurately but without similar insight into the effi-
cacy/effectiveness profile.
Hence, although the FDA guidance infers that PRO
instruments should aim to measure the adverse conse-
quences of treatment separately from the effectiveness of
treatment, more recent methodologies would support effi-
cacy (or effectiveness) data being collected from the same
dataset as safety, and may in fact improve the utility of the
information [33]. Although the context for the FDA and
EMA documents is to develop PRO instruments to support
Table 5 Example approach for developing a PRO-AE instrument
Stage Brief description Details
Stage 1 Development of the conceptual framework 1. Identification of concepts and domains that are to be measured
2. Identification of the purpose of the PRO instrument
3. Identification of the intended population
Stage 2 Creation of the PRO instrument. [Criteria vary depending on
whether developing a targeted measure to look at a particular
AE (e.g. to compare tolerability in a phase 3 clinical trial) vs.
general/generic screening questions. In the latter case, single
items for each PRO-AE can be developed and broadly used]
1. Generation of items
2. Choice of response options
3. Evaluation of patient understanding
4. Development of instructions and training
5. Identification of preliminary scoring of items and domains
6. Assessment of respondent and administrator burden
7. Confirmation of the conceptual framework and finalisation of
the instrument
Stage 3 Embedding of patient perspective [37]
(This stage can be performed in parallel with Stage 2)
1. Generate disease area candidate items (if required), in addition
to generic items, with input from qualitative interviews with
patients, and add those items to the core instrument for testing
2. Drop any candidate items that lack sensitivity
3. Validate the psychometric properties (validity, reliability,
sensitivity) of the resulting instrument
4. Conduct cognitive debriefing interviews with patients to
confirm the instrument’s ease of comprehension, relevance and
acceptability
Stage 4 Assessment of measurement properties 1. Evaluation of reliability, e.g. what level of evidence (how large
a patient sample)
2. Assessment of validity
3. Evaluation of ability to detect change
4. Choice of methods for interpretation
a. Definition of responders
b. Definition of a minimum important difference
Stage 5 Instrument deployment plan 1. Determine format
2. Determine timing
3. Determine appropriate collection method
Stage 6 Modification of instrument 1. Revised measurement concept
2. Application to a new population or condition
3. Changed item content or instrument format
4. Changed mode of administration
5. Changed culture or language of application
6. Test modified instrument with patients
Some steps may be combined or shortened, particularly if adapting social media for non-structured, non-prespecified reports
AE adverse event, PRO patient-reported outcome, PRO-AE patient-reported outcome of adverse event
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labelling, there are some methods in these guidances that
may apply to non-labelling objectives.
PRO-AE instruments, like PRO instruments in general,
need to be validated and ‘fit for purpose’, i.e. practical for
use by patients, to encourage reporting, and interpretable
by a number of stakeholders (prescribers, regulators,
industry, policymakers and, not least, patients themselves).
The following subsections address:
1. A process for developing PRO-AE instruments;
2. Creating a suitable taxonomy;
3. Selecting appropriate technologies;
4. The availability of alternative data sources;
5. The relationship between PRO-AEs and AE data from
other sources.
5.1 Process for Developing PRO-AE Instruments
A suitable framework for developing PRO-AE instruments
should be used. An example is given here, which was
adapted by the Patient-Reported Outcomes Safety Event
Reporting (PROSPER) Consortium in a series of iterative
discussions and reviews from an approach presented by the
FDA in their guidance document [16]. The details associ-
ated with each stage are presented in Table 5, which may
be iterative. Optional method-specific steps that may be
needed are shown in Table 6.
A PRO initiative by the National Quality Forum in the
USA has suggested that characteristics for a good PRO
instrument for AEs and other usages include actionability,
meaningfulness to both patient and HCP, facilitation of
shared decision making between patient and HCP, and
implementability [33].
Some instruments designed to capture adverse effects
systematically are available, and have been shown to
improve care [34, 35]. Nurses, as the professionals closest
to patients, may be best placed to lead the profiling of
patient problems. Ensuring that single pertinent questions
capture clinically important symptoms efficiently requires
cognitive input from both HCPs and patients [36].
5.2 Creating a Suitable Taxonomy
One issue with the development of PRO tools, and espe-
cially those used for collecting AE data, is the creation of a
taxonomy by an iterative process. In one study, terms were
aligned with the existing Medical Dictionary for Regulatory
Activities (MedDRA) and refined with input from patients,
including comprehension testing within which patient-
reported symptoms were categorised and defined [7]. Once
achieved, patient-reported symptoms and AEs were gener-
ally in agreement with those reported by clinicians and
nurses. The PRO tool used in this study was a modified
version of the CTCAE using 13 terms familiar to cancer
patients. Cirillo et al. [7] have shown that a modified version
of the dictionary used in trials can be utilised in the post-
marketing setting by patients undergoing chemotherapy.
The development of a patient-friendly dictionary is an
important consideration when developing PRO-AE tools to
encourage reporting of PRO-AEs. An alternative approach
being investigated by the World Health Organization
(WHO)/Uppsala Monitoring Centre (UMC) consists of an
anatomical interface to help patients identify appropriate
AR terms. The electronic interface uses the image of a
body, and clicking on a particular area drills down to
present AR terms associated with that body area (WHO/
UMC, unpublished communication).
5.3 Selecting Appropriate Technologies
In clinical trials, most PRO-AE reporting systems have
been paper based. However, the NCI has developed a web-
based platform for CTCAEs, as well as standard paper
channels. The equivalency between web-based and other
traditional channels is currently being tested. This initiative
was undertaken to develop a system that would be used by
patients to report adverse symptoms in cancer trials; gen-
erate useful data for investigators, regulators, clinicians,
academic groups and patients; and be compatible with
existing AE reporting systems [28].
For marketed drugs, there have been web-based systems
allowing patients to report suspected ARs directly to the
regulators in the UK, Denmark, Netherlands, US, Sweden,
etc. Recent EU pharmacovigilance legislation has included
a requirement for direct patient-reporting mechanisms to
regulatory authorities.
The WHO/UMC is also developing a web-based system
for patient self-reporting of AEs (WHO/UMC, unpublished
Table 6 Additional steps that may be required in the example
approach
Additional step Comment
The need to perform a quality
check before passing from one
stage to the next, to ensure each
element in the stage has been
completed satisfactorily
Need checklists to determine
whether each stage is
completed appropriately
This intrinsic quality assurance
should include a consideration
of utility versus quality
The need to return to a previous
stage and repeat the activities,
possibly due to new
information or a change in one
or more criteria
Iteration is important, and in
particular is essential in real-
world usage
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communication). In contrast, some non-regulatory websites
are not exclusively used to collect PRO-AEs, but are
designed to be consumer friendly.
When developing PRO-AE instruments, there is a need
to consider the most appropriate technology. However,
deploying PRO-AE instruments through the internet or
through smart technologies such as phones and tablets does
require consideration to be given to:
1. Access to technology;
2. Data privacy and storage issues;
3. Appropriateness for the population;
4. Data transmission;
5. Cost;
6. Technical awareness of patients—since the dataset will
be biased if only technically aware patients report;
7. Patient knowledge of the ability to report and patient
willingness to report;
8. Data privacy and protection.
5.4 Availability of Alternative Data Sources
Data from existing patient sources including electronic
patient records are routinely collected in primary care
and may be suitable for AE screening, such as patient
safety indicators, and to validate novel PRO-AE
instruments.
The current FDA Sentinel Initiative is aiming to develop
a national electronic safety monitoring system by aug-
menting existing safety monitoring systems. This has been
achieved by leveraging multiple sources of electronic data
through partnering with data holders and use of a common
data model for healthcare systems, insurance companies
and industry, with potential coverage of up to a third of the
US population. Although currently not in Sentinel, large
datasets such as this would be enhanced by systematically
collected PRO-AE data.
The advantages of this approach include enhancing the
active post-marketing monitoring of medical product safety
to effectively and rapidly examine common outcomes (e.g.
myocardial infarction, fractures) in large, real-world pop-
ulations, with improved access to subgroups and special
populations. Additionally, validated quantitative approa-
ches have been developed for signal refinement using
sequential monitoring of single time points with adjust-
ments to minimise confounding, near real-time monitoring
and an accessible library of tools/resources.
5.5 Relationship Between PRO-AEs and AE Data
from Other Sources
There are various models that can be employed and the
approach should be prespecified [19]:
1. Independent reporting, in which AE data gathered
from the patient and the clinician are collected,
analysed, and reported completely separately from
each other. A subsequent comparison of the common-
alities and differences between the patient-reported
and clinician-reported data may provide valuable
insights.
2. Merged reporting, in which AE data gathered from the
patient and the clinician are collected separately but
then merged and analysed together. However, this is a
challenging goal, so in many situations, it is preferable
to keep the two data pools of clinician- and patient-
collected AEs separate to aid meaningful interpretation.
3. Collaborative reporting, in which AE data gathered
from the patient is then provided to clinicians to
inform their reporting. Specific trials might be needed
to test the utility and validity of this concept.
The choice of approach depends on whether two specific
pools of information, from patients or from medically
confirmed sources, can be combined or whether, because
they provide discrete data with different utility, they must
be separately stored and analysed. Another factor is the
impact of feedback of PRO-AE information on stakeholder
behaviour (including prescribers and patients).
A formal comparison of these three approaches is
planned as a part of the NCI’s PRO-CTCAE initiative [28].
In total, there are 124 questions that assess different attri-
butes (e.g. presence, frequency, severity, interference) of
78 symptoms that are represented in both the CTCAE
(version 4) and MedDRA AE lexicons. Using cognitive
testing, these 124 questions have been extensively evalu-
ated by cancer patients, and have been found to be com-
prehensible and to measure the symptom of interest. An
electronic system provides a mechanism for scheduled
periodic surveillance and collection of patient-reported
symptom data, using the web or a touch-tone telephone. US
validation study complete and reported at international
meetings, with robust psychometric properties shown for
Table 7 Currently available datasets for adverse events data capture
Dataset
• CIOMS I or MedWatch 3500 form (see Appendix: ESM 1 and 2)
• Minimum elements (identifiable patient, suspected drug,
suspected adverse reaction, identifiable reporter)
• ICH E2B (see Appendix: ESM 3)
• Free text (linked to free text mining/coding)
• Additional specific datasets relevant to drug/class/disease
CIOMS Council for International Organisations of Medical Sciences,
ESM electronic supplementary material, ICH International Confer-
ence on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use
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most items. Linguistic adaptation to multiple languages is
ongoing, and there are multiple ongoing trials assessing the
feasibility of this approach [28].
6 Data Capture and Appropriate Datasets
As already shown in Fig. 1, it is envisaged that PRO-AE
instruments will be used to collect different datasets at
different stages of drug development. These data in turn
will be used to measure different concepts and domains.
Because of this, an important part of PROSPER’s remit
is to investigate what PRO-AE datasets might be appro-
priate when addressing different concepts and domains.
Table 7 identifies some of the common AE data collection
tools currently in use. European regulatory authorities are
also developing standard, structured forms specifically for
web-based reporting of suspected ARs by patients as well
as HCPs.
However, tools such as CIOMS I, MedWatch 3500 and
ICH E2B may not be suitable in their full form for use as
PRO-AE instruments. These may require editing, with a
focus on the PRO concepts/domains being measured, down
to a core dataset suitable for PRO-AEs in non-prespecified
patient populations. There may also be a need to add some
further terms to optimise PROs for patient safety and
benefit–risk analysis, e.g. severity as well as seriousness.
An attempt has been made to identify the minimum
number of fields in the CIOMS I and MedWatch forms [see
Appendix: electronic supplementary material (ESM) 1 and
2] that could provide valuable PRO-AE data. We have also
identified those fields in the ICH E2B dataset that would
provide the ‘gold standard’ in terms of PRO-AE data (see
Appendix: ESM 3). The general aim should be to have
enough fields completed by patients to allow easy linkage
to individual case study reports (ICSRs) from health pro-
fessionals, so that these reports may be used together as
well as separately.
However, another approach would be to identify the
PRO concept or end point that is being assessed and
identify the minimum fields needed to determine this value.
This may necessitate identifying new fields, e.g. the
question ‘‘Has a report been submitted by your doctor or
HCP?’’ could result in yes/no/I don’t know options being
offered, and the ‘‘yes’’ option would mean that additional
information may be required, such as HCP name.
Once a mechanism has been put in place to capture
PRO-AEs, a key consideration is how to raise patient
awareness to actively provide unsolicited PRO-AEs.
Guidance should also include a framework to define
how data are managed, including any data privacy issues:
• When data are collected, what are the rules of
engagement?
• What will be collected?
• What will be received (by pharmaceutical companies/
regulators)?
• How will it be validated? The WHO/UMC has
investigated this issue, and within its organisation, uses
an instrument to score the validity of a report [38, 39].
• How will duplicates be detected? For example, the ‘hit-
miss model’.
Who performs these tasks is of less importance as long
as the framework is clear about what needs to be done.
However, if a pharmaceutical company is provided with
the raw database, then this would trigger reporting
responsibilities under current regulations. For the use of
similar healthcare databases, personal details are of course
already removed (i.e. anonymised databases) for reasons of
confidentiality.
7 Analysis of PRO-AE Data
As already discussed, a useful way of classifying PRO-AEs
is to relate them to the main population types under
investigation, i.e. prespecified and non-prespecified. Fur-
ther stratification can be provided by considering whether
the AE data collected are structured or unstructured, and
whether or not the patient selection method is more or less
restrictive (see Fig. 1). Analyses of PRO-AEs from pre-
specified and non-prespecified patient populations need




In early clinical trials, the safety evaluation is exploratory and
is only capable of detecting direct expressions of toxicity
In later phases, where sample sizes are greater, the safety
profile of a drug can be characterised more fully. Comparison
with efficacy data informs the benefit–risk profile
In post-approval studies, the safety profile can be
further characterised. Comparison with efficacy or





Detection of low-probability signals from a larger, non-prespecified patient population
Data on real-work safety profile (e.g. with concomitant medication and medical conditions)
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different methodologies, including definition of a core
safety dataset to permit useful signal detection. Where
possible, measuring baseline symptoms gives a useful
additional perspective.
Patient-reported safety information that better reflects
the ‘real world’, i.e. with a non-prespecified population and
non-structured datasets, has increased medical relevance.
However, this must be balanced against quantitative
validity (see Fig. 1), at least against the current agreed
standards of data from randomised, blinded and controlled
trials.
This section considers how analytical robustness of
patient-reported safety outcomes can be preserved within
these more real-world settings, as well as more controlled
settings such as pre-approval clinical trials.
7.1 Scope of the Evaluation
7.1.1 Prespecified Populations
In early clinical trials, the safety evaluation is exploratory
in nature and is primarily used to delineate the toxicity
boundaries of the dose-response curve (Table 8). However,
direct PRO-AE measurements could be used at this stage to
screen for unexpected reactions and, if their incidence and
severity were confirmed in phase 3 trials, used to support
filing/registration claims.
Although there are inherent limitations with pre-
approval safety evaluations, such as small sample size,
narrow eligibility criteria and limited duration of follow-
up, their ability to detect adverse symptom events among
study participants improves with the use of clear dataset
definitions, methodology for collection, and agreed ana-
lytic approaches.
PRO-AE measurements could also be used for post-
approval signal detection or for targeted assessments in
phase 4 controlled trials.
As discussed in Sect. 5.5, safety data collected via PRO-
AE instruments can potentially be analysed independently
from or in combination with AE data from other sources.
These data can also be used to inform the benefit–risk
balance of a product by including in the analysis efficacy or
effectiveness data, which may also include PROs.
7.1.2 Non-prespecified Populations
Post-approval safety data are useful for general screening
to detect low-frequency safety signals through the
exploitation of a larger user population, even from non-
prespecified populations. In addition, other PRO-AE-
based PASS study designs may benefit from proactive
patient follow-up for occurrence of AEs of special
interest.
Consequently, the main question is, can PRO-AE data
be amalgamated with data from other sources? Low-fre-
quency safety signals may potentially have a significant
impact on the benefit–risk profile of a product.
7.2 Choice of Variables and Data Collection
In both the pre- and post-approval phases, the occurrence
of serious AEs and treatment discontinuations due to AEs
are particularly important to identify. If PRO-AE tools are
utilised, a common AE dictionary that allows patient-
reported data to be summarised and collated is important
(Table 9). This might necessitate the development of a set
of terms that are understood by the patient and can be
mapped to higher level ‘medical’ terms, similar to the
PRO-CTCAE dictionary developed by the NCI for oncol-
ogy trials [28]. In addition, a severity scoring system for
pre-agreed PRO-AEs can be developed. For example, in
the case of a symptom like rash, questions will focus on its
location on the body.
Table 9 Data collection considerations
Population Pre-approval Post-approval
Prespecified (structured) If PRO-AE tools are used to collect clinical AEs,
then the development of a patient-centric
dictionary needs to be considered
A dataset suitable for the study needs to be established
Non-prespecified (structured) Patient could potentially report on a social
website AEs from a clinical trial where the
website offers structured collection
Regulated consumer sites (e.g. MHRA-Yellow Card) have
a well-defined dataset. Some patient support sites are also
structured
If PRO-AE tools are used to collect AEs, then the




Patient could potentially report on a social
website AEs from a clinical trial
For PRO-AEs from non-regulated consumer sites, a
minimum dataset needs to be agreed
AE adverse event, MHRA Medicines and Healthcare Products Regulatory Agency, PRO-AE patient-reported outcome of adverse event
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7.2.1 Prespecified Populations
In pre-approval clinical trials, data from objective labora-
tory tests, clinical variables (blood pressure, pulse, respi-
ratory rate) and investigations (e.g. radiology) usually form
a major part of the safety data. These types of data are
reported directly and their transmission by patients would
not normally be expected as part of a study. However,
clinical AEs (diseases, signs, and symptoms) would be
suitable for PRO-AE methods, although of these, a strong
emphasis would be placed on patient-reported symptoms.
7.2.2 Non-prespecified Populations
A rapidly increasing quantity of patient-reported data is
available on the internet. Unstructured data can present a
particular challenge for extracting useful information, since
the data are usually incomplete. PRO-AE-enabled websites
allow a more structured approach, where the dataset can be
designed pre-emptively, and so are far likelier to provide a
higher quality of data.
7.3 Defining the Evaluable Population
7.3.1 Prespecified Populations
For pre- and post-approval clinical trials, the evaluable
population for PRO-AE comparisons is usually defined as
those subjects who received at least one dose of the
investigational drug, as well as any comparator drug/pla-
cebo groups (Table 10). Safety variables should be col-
lected as comprehensively as possible from these
participants, including type of AE, severity, onset, and
duration. Additional safety evaluations may be needed in
specific subpopulations, such as females, the elderly, the
severely ill, or those who have a common concomitant
treatment.
All relevant safety variables will be evaluated, and the
broad approach should be indicated in the protocol. All
AEs should be reported, whether or not they are consid-
ered related to treatment. All available data in the study
population should be accounted for in the evaluation.
Definitions of measurement units and reference ranges of
laboratory variables and other investigations should be
made with care; if different units or different reference
ranges appear in the same trial (e.g. if more than one
laboratory is involved), then measurements should be
appropriately standardised to allow a unified evaluation.
Use of a toxicity grading scale should be prespecified and
justified. Definition of PRO symptom severity scales, e.g.
for pain, nausea, etc., can also be standardised between
studies.
The incidence of an AE is usually expressed in the form
of a proportion relating number of subjects experiencing
events to the number of subjects at risk.
7.3.2 Non-prespecified Populations
Where PRO-AEs are being used in the post-approval phase
with non-prespecified populations, the safety variables
should be collected as comprehensively as possible from
these subjects, including type of AE (using appropriate
terms), severity, onset, and duration. Evaluable subjects are
those for whom a retrospectively defined set of data ele-
ments is available. A suggested minimum dataset is pro-
vided in the Appendix (see the ESM), to which severity,
onset and duration could also be added.








Patients could potentially report on a social website AEs
from a clinical trial where the website offers structured
collection
Currently, for regulated and non-regulated consumer sites,
evaluable subjects require an identifiable patient, suspected
drug, suspected AR and identifiable reporter as the minimum
dataset
In the current guidance, a core minimum dataset is proposed in




Patient could potentially report on a social website AEs
from a clinical trial
For non-structured social networking sites, e.g. Facebook, a
minimum dataset needs to be agreed. Comparator groups need
particular consideration as any detection of safety signals will
have to be done over and above the background rate for a
‘comparable’ population not receiving the drug/device.
Identifying the comparator population will be further
complicated in a self-reporting, social network environment
AE adverse event, AR adverse reaction, ESM electronic supplementary material, PRO-AE patient-reported outcome of adverse event
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7.4 Statistical Evaluation Techniques
7.4.1 Prespecified Populations
Because, prior to approval, the range of possible adverse
effects is very large, the assessment of unexpected PRO-
AEs must be built into all protocols. As a result, the safety
data (whether collected in the traditional manner or via a
PRO-AE tool) are best addressed by applying descriptive
statistical methods to the data, supplemented by calculation
of confidence intervals wherever this aids interpretation. It
is also valuable to make use of graphical presentations in
which patterns of AEs are displayed both within treatment
groups and within subjects. For example, presenting, in
ascending order of risk, a series of AEs for the comparator
and active drug together with their relative hazard ratio and
confidence intervals is a good visual technique.
The calculation of p values can be useful to identify a
specific difference or as a flagging device applied to a large
number of safety variables to highlight differences worthy
of further attention.
If hypothesis tests are used, statistical adjustments for
multiplicity to quantify the Type I error are appropriate, but
the Type II error is usually of more concern [40]. Care
should be taken when interpreting putative statistically
significant findings when there is no multiplicity
adjustment.
In the majority of trials, investigators are seeking to
establish that there are no clinically unacceptable differ-
ences in safety compared with either a comparator drug or
placebo. As is the case for non-inferiority or equivalence
evaluation of efficacy, the use of confidence intervals is
preferred to hypothesis testing in this situation. In this way,
the considerable imprecision often arising from low fre-
quencies of occurrence is clearly demonstrated [40].
7.4.2 Non-prespecified Populations
There are a number of available approaches to aid the
interpretation of PRO data, which could be adapted to
PRO-AE data. They cover a spectrum of standard types of
analyses for these types of data, including descriptive sta-
tistics, data mining/disproportionality, and multivariate
analyses (Table 11).
Other approaches include comparing a PROMs score
with known clinical parameters, such as days in hospital
and illness severity [41], the proportion of patients whose
PROMs scores improve or worsen after intervention [42],
and cross-instrument calibration using advanced statistical
analyses such as item response theory (IRT) [43]. Although
not specific to PRO-AE evaluation, such techniques might
assist the quantification and assessment of patient-reported
benefit–risk profiles. For longitudinal data, comparison of
patient-level AUCs, or cumulative incidence of worst
severity scores may be performed.
The test for statistical significance will depend on the
approach used for the data analysis. This may include
p values, standard deviations, and/or confidence intervals.
The use of statistics based on disproportionality is also
possible in non-prespecified populations with non-struc-
tured datasets, but more innovative approaches are needed
for this group (see next section on data mining).
7.5 Data Mining Techniques
The use of data mining for signal detection during clinical
trials is a relatively new concept and allows researchers to
perform ad hoc and close-to-real-time data analysis,







• Numbers and percentages
• Chi-squared test
• Mean (e.g. known groups—the mean scores
underlying particular clinical groups which
can be used as a benchmark to compare other
groups; normative and reference groups—
customised benchmarks to compare other
groups)
• Minimal important difference (MID)—from
the patient perspective, can be defined as ‘‘the
smallest difference in score in the domain of
interest which patients perceive as beneficial
and which would mandate, in the absence of
troublesome side effects and excessive cost, a
change in the patient’s management’’ [44]
• Incidence and/or prevalence
• Relative risk or odds ratio
Disproportionality—the occurrence of a drug–
event pair at a higher frequency than would
be expected from a statistically independent
random occurrence
A) Frequentist methods
• Proportional reporting ratio (PRR)—a
measure of the disproportionality
• Reporting odds ratio (ROR)
B) Bayesian methods
• Bayesian confidence propagation neural
network (BCPNN)





• Cox proportional hazard models
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reducing time in the interchange between researchers, cli-
nicians and statisticians [45].
Traditionally, analysis has been carried out by a sys-
tematic manual review of every report sent by physicians to
pharmacovigilance experts. These reports are registered in
pharmacovigilance database systems.
More recently, automated signal detection methods have
been developed to supplement qualitative clinical methods
(see Table 12 and ESM 4). While these automated methods
cannot replace expert clinical reviewers, they can assist
with the difficult task of screening huge numbers of drug–
event combinations in databases for potential signals.
Through commonly used methods that are based on an
underlying model of statistical association, databases are
scrutinised for a significant occurrence of disproportional-
ities or dependencies between drug–event pairs.
The WHO/UMC and the FDA are currently using
automated detection algorithms based upon Bayesian ana-
lysis to achieve signal generation. These methods have a
major role in prioritising signals by disproportionality,
which are then clinically reviewed. The validity of the
approach has been demonstrated in several papers and is
now routinely practised [46]. Though the optimum algo-
rithms are not established, there is much work being done
in this area through the OMOP project [47–50].
Work has also been commenced on natural language pro-
cessing to allow analysis of narratives and related terms [51].
MedDRA is the unified standard terminology currently
used for recording and reporting adverse drug event data in
most countries, but it may be necessary to extend/adapt it
to include certain patient-reported terms being mapped to
already accepted Preferred Terms (PTs)/Lower Level
Terms (LLTs). In the meantime, verbatim terms reported
by the patient can be reported directly, or grouped together
into recognised symptom PTs.
Methods based on data warehousing and statistical
analysis techniques provide various algorithms to identify
trends or clusters of events, which may increase the
accuracy and reliability of interpretation of safety data. The
basic components are already available to companies for
performing data mining of these safety databases for
pharmacovigilance.
Statistical analysis system (SAS) tools are available for
analytic processing, particularly to create complex analyses
and reports. Utilising a suite of other SAS solutions enables
companies to perform proactive pharmacovigilance. This
suite may include data integration and tools to support
clinical trials and drug development, which provides a
standard, compliant environment for storage, retrieval,
analysis, reporting and signal detection.
The signal detection process used by the WHO/UMC for
analysis of VigiBase Centre consists of a combination of
automated knowledge discovery methods [52], triage
(prioritisation) algorithms and clinical review [53]. The
knowledge discovery methods highlight drug–AR pairs
with unexpectedly large numbers of reports relative to the
average reporting ratios in the database. Triage algorithms
use a combination of quantitative and qualitative infor-
mation to focus attention on the key issues for follow-up
[53]. Reports related to drug–AR pairs picked out by the
triage algorithms are sent to an expert review panel, with
pattern discovery methods often useful for profiling groups
of reports and suggesting alternative explanations for
increased reporting.
Hypotheses of suspected ARs first highlighted in auto-
mated knowledge discovery, which remain after clinical
review, are then communicated to industry/regulators and
published as appropriate [54, 55]. However, the risk of
distortion from undiscovered data quality problems and the
difficulty of obtaining complete, detailed information on








Patient could potentially report on a social
website AEs from a clinical trial where
the website offers structured collection
Automated signal detection is well established and relies on data
warehousing of large numbers of spontaneous reports and statistical
analysis techniques
Data mining techniques include:





Patient could potentially report on a social
website AEs from a clinical trial
Data mining encounters problems with use of natural language and the
interpretation of free text responses. Need advances in natural language
processing for data mining free text, currently work in progress by
WHO/UMC
AE adverse event, UMC Uppsala Monitoring Centre, WHO World Health Organization
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reported AR incidents mean that signals of suspected ARs
often remain tentative, even after clinical review [56].
A knowledge discovery process has been applied to the
WHO/UMC VigiBase to resolve some of these shortcom-
ings by examining the entire AR signal detection process
[56]. The steps covered were data collection, cleaning and
preparation; reduction and projection; data analysis and
interpretation; and finally dissemination, incorporation into
existing structures and action based on discovered knowl-
edge. A duplicate detection method (the hit-miss model)
that can reliably identify pairs of unexpectedly similar
reports and a new measure for highlighting suspected drug–
drug interaction have also been validated on the WHO/
UMC database, which could be applied to compare PRO
databases with overlapping medically confirmed sponta-
neous reports [56].
Examples of data mining techniques and related analytic
approaches including predictive modelling, clustering or
database segmentation, link analysis, and deviation detec-
tion are shown in ESM 4 in the Appendix (adapted from
[57]).
8 Data Protection
Collection of identifiable patient data needs to meet the
various international, regional (e.g. EU) and national data
protection legal requirements, as appropriate. For exam-
ple, real-world collection of identifiable patient data on
the web, particularly when solicited as structured reports
in the post-approval setting, must be done in a manner
consistent with the relevant data protection legislation.
The problem is complicated by the fact that the legislation
would normally be enforceable in the country where the
web collection tool originates, and also where any data is
stored for safe harbour. Patients, of course, may be able to
access and input their own data from other countries, and
it is unclear to what extent these other countries’ data
protection laws, if different from the enforceable country,
need to be met.
9 Conclusions
The patient perspective is an essential component of drug
safety profiles. Within this document, the PROSPER
Consortium sets out an innovative framework for improv-
ing safety data during both clinical development and post-
marketing phases by integrating the patient’s voice and
perspective.
This comprehensive guidance suggests methods for
including PRO-AEs as part of any structured questionnaire
design, which may be used in both specified and non-
prespecified populations. There is a valid distinction
between the assessment and data mining of grouped,
safety data, giving aggregate patterns of PRO-AE infor-
mation, which do not necessarily require medical confir-
mation on an individual basis, as opposed to the
assessment of single cases for which medical confirmation
remains important.
The guidance proposes a minimum core dataset for use
with unstructured data sources, details of which are pro-
vided in the Appendix (see the ESM). Various approaches
to analytic methodology are considered, with the method of
choice dependent on the specific patient-reported data
being collected. For larger, non-prespecified populations
and unstructured data, the quantitative methodology will
require the use of more novel and emerging data mining
approaches.
Patient-centeredness and patient safety are emerging as
core elements of any responsive health system. As patients
become more activated in their health and healthcare, they
support the maxim of ‘‘Nothing about me, without me’’ and
expect others involved in their care to engage in shared
decision making, so that what matters to the patient is
always included.
As stated at the outset of this document, the potential
clinical utility and value of real-world information obtained
from real patients taking real drugs is great [58]. Techno-
logical advances that were not available even a decade ago
now offer unprecedented access for multidirectional com-
munication between patients, clinicians, the private sector,
industry and regulatory authorities.
We believe that the current guidance will help ensure
that the voice of the patient will be heard, so that the safety
profile and hence benefit–risk balance of new and existing
medicines is better defined.
10 Glossary
Adverse event (AE): Any untoward medical occurrence in
a patient or clinical trial subject administered a medicinal
product, which does not necessarily have to have a causal
relationship with this treatment [Dir 2001/20/EC 76 Art
2(m)]. An AE can therefore be any unfavourable and
unintended sign (e.g. an abnormal laboratory finding),
symptom, or disease temporally associated with the use of
a medicinal product, whether or not considered related to
the medicinal product [15].
Adverse reaction (AR): A response to a medicinal product
that is noxious and unintended [DIR 2001/83/EC Art
1(11)]. ‘Response’ in this context means that a causal
relationship between a medicinal product and an AE is at
least a reasonable possibility.
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Common Terminology Criteria for Adverse Events
(CTCAE): A dictionary developed by the US NCI
designed for use in clinical trials to aid clinicians in
detecting and documenting AEs commonly encountered in
oncology treatment.
Concept: The specific goal of measurement, i.e. the thing
that is to be measured by the PRO instrument.
Data mining: The process of extracting meaningful pat-
terns from large datasets using automated computational
and statistical tools and techniques.
Disproportionality: Disproportionality analysis is an
important tool for identifying new signals/patterns in
spontaneous AE report databases. There are a variety of
disproportionality measures (DPMs) used in safety sig-
nalling. DPMs are based on the ratio of the number of
observed (O) cases and the number of expected (E) cases
(i.e. O/E).
Domain: In a PRO instrument, a domain is a discrete
concept within a multi-domain concept. All of the items
within a single domain contribute to the measurement of
the domain concept. The domain could be, but is not
necessarily, considered a specific end point within the
overall conceptual model.
Harm: Adverse impact on an individual’s health status.
Healthcare professional (HCP): Any qualified profes-
sional involved in the delivery of healthcare to the patient,
whether or not involved in prescribing. Specifically, this
term includes doctors, prescribers other than doctors,
pharmacists, nurses, dieticians, and physiotherapists.
Health-related quality of life (HRQoL): A multi-domain
concept that represents the patient’s overall perception of
the impact of an illness, its treatment, and their overall state
of health on their quality of life. This concept is used in
FDA PRO effectiveness guidance (FDA, 2009).
Instrument: A structured means to capture PRO data, e.g.
a questionnaire or diary along with supporting information
such as training materials, scoring, etc. In the context of
this guidance, this could be a specific reporting tool that
through completion generates a structured dataset.
Item: An individual question within a PRO instrument that
is evaluated by the patient.
Non-prespecified population: A group of patients where
the number and type of patients included has not been pre-
agreed.
Non-regulated consumer website: A website that is not
set up with an aim to collect PRO-AEs, and where data
posted will therefore be unstructured, and safety informa-
tion posted is, at best, reviewed and collected.
Non-structured data: Data recorded without a data model.
Patient-reported outcome (PRO): The concept of any
report of the status of a patient’s health condition that
comes directly from the patient, without interpretation of
the patient’s response by a clinician or anyone else. For the
purposes of this guidance, PROs are defined as encom-
passing the full range of self-reporting, ranging from those
data collected via a structured and validated questionnaire
to those collected in a free-text manner via spontaneous
patient submissions (or in some cases from caregivers or
surrogates).
Patient-reported outcome of adverse event (PRO-AE):
A PRO-AE is any untoward medical occurrence, whether
or not considered treatment/intervention related, which is
reported or transmitted directly by the patient without
interpretation by a clinician or anyone else. PRO-AEs may
be collected by both structured and unstructured reports.
Patient-reported outcome measures (PROMs): An
instrument, scale or single-item measure used to assess the
PRO concept as perceived by the patient, obtained by
directly asking the patient to self-report. The term has also
been used in the UK-NHS, in the context of patient satis-
faction, symptoms and functional status measures in rela-
tion to selected surgical procedures. In the context of
epidemiology, AE outcome measures can be continuous
variables or have binary outcomes.
Patient-reported outcomes version of the Common
Terminology Criteria for Adverse Events (PRO-
CTCAE): A specific subset from the US NCI CTCAE
project taxonomy; work is in progress.
Patient support programme (PSP): Sometimes also
called ‘patient assistance programmes’, these may com-
prise non-interventional observational study designs or
medical enquiry/patient assistance services. Safety report-
ing processes should be clearly defined by the market au-
thorisation holder before the programme commences, to
ensure that serious and non-serious AR reports are cap-
tured, as appropriate, and that causality assessments and
regulatory reporting are performed, where required.
Post-approval/post-authorisation: Occurring after a
medicinal product has received regulatory approval (post-
licensing).
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Pre-approval/pre-authorisation: Occurring prior to a
medicinal product receiving regulatory approval.
Prespecified population: Enrolment of a specific patient
group in conformance with a pre-agreed number and
patient type or profile. This profile may be restricted (with
inclusion/exclusion criteria) or unrestricted (no specific
inclusion/exclusion criteria, but the size and/or geography
of the group could still be limited).
PRO-AE-enabled patient support website: A specific
website (whether company sponsored or not) that uses
structured data collection in a scientifically robust way and
is designed for patient education, interaction and self-
reporting of PRO-AEs via a structured data collection
instrument.
PRO-enabled: Data collection processes/systems and
technologies that are adapted for the collection of patient-
reported outcomes.
Registry: A defined group of patients, whether having a
specific exposure (e.g. taking one or more specific treat-
ments) or having a specific disease (i.e. a disease registry).
A registry may be prespecified (pre-agreed dataset) or non-
prespecified (open enrolment).
Regulated consumer website: A website that is set up
with an aim to collect PRO-AEs, and where data posted
may be either structured or unstructured, but safety infor-
mation posted is regularly reviewed and collected.
Risk: Defined by the UMC as ‘‘the probability of harm
being caused; the probability (chance, odds) of an occur-
rence’’. The EU defines ‘‘risks related to use of a medicinal
product’’ as ‘‘any risk relating to the quality, safety or
efficacy of the medicinal product as regards patients’ health
or public health; and any risk of undesirable effects on the
environment’’ [DIR 2001/83/EC Art 1(28)].
Social network site: Web-based services that allow indi-
viduals to construct a public or semi-public profile within a
bounded system; articulate to a list of other users with
whom they share a connection; and view and traverse their
list of connections and those made by others within the
system. Non-medical social network sites are not specifi-
cally designed for a treatment or disease, but are where
PRO-AEs may be reported incidentally, often in an
unstructured way (e.g. Facebook or Twitter).
Structured data: An organised dataset based on a data
model, in contrast to unstructured data that consists of open
text fields.
Validation: The process of evaluating a PRO instrument’s
ability to measure a specific concept or collection of con-
cepts accurately.
Voluntary enrolment: Where patients are able to enrol
themselves, whether prespecified (usually in the post-
approval setting) or non-prespecified.
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